drugset

drugset / Trial / NCT02728180

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

NCT02728180 ↗

Phase 4 Unknown 720 enrolled Dongzhimen Hospital, Beijing Beijing Chao Yang Hospital · collab Beijing Emergency Medical Center · collab Beijing Tiantan Hospital · collab Cangzhou Hospital of Integrated Medicine · collab Chengdu University of Traditional Chinese Medicine · collab China-Japan Union Hospital, Jilin University · collab Chongqing Traditional Chinese Medicine Hospital · collab Deyang People's Hospital · collab Guangdong Provincial Hospital of Traditional Chinese Medicine · collab Hunan Academy of Chinese Medicine · collab Jiangmen Wuyi Hospital of Traditional Chinese Medicine · collab Jiangxi Provincial People's Hopital · collab Liling Hospital of Traditional Chinese Medicine · collab Mianyang Central Hospital · collab Shaanxi Hospital of Traditional Chinese Medicine · collab Shaanxi Provincial People's Hospital · collab Shandong University of Traditional Chinese Medicine · collab The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · collab The Fifth People Hospital of Chongqing · collab The First Affiliated Hospital of Henan University of Traditional Chinese Medicine · collab The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine · collab The First Hospital of Jilin University · collab The First Hospital of Wuhan · collab The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine · collab The Second Hospital of Hebei Medical University · collab Tianshui Hospital of Traditional Chinese Medicine · collab Wuxi Hospital of Traditional Chinese Medicine · collab Yantai Yuhuangding Hospital · collab Zhejiang Provincial Hospital of TCM · collab Zhejiang Provincial Tongde Hospital · collab Zhongshan Hospital Of Traditional Chinese Medicine · collab Zibo Hospital of Traditional Chinese Medicine · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

The main purpose of this trial is to determine whether Xingnaojing, intravenously administered within 24 hours of symptom onset, improves the 3-month outcome in participants with acute ischemic stroke.

Timeline

Start: 2016-03
Primary completion: 2019-12-31
Completion: 2019-12-31

Publications

Background Lai X, Cao K, Kong L, Liu Q, Gao Y; XMAS study investigators. Xingnaojing for Moderate-to-severe Acute ischemic Stroke (XMAS): study protocol for a randomized controlled trial. Trials. 2017 Oct 16;18(1):479. doi: 10.1186/s13063-017-2222-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Xingnaojing	Unknown	20 ml	Intravenous

Indications